The risk of early and late cytomegalovirus DNAemia associated with Campath use in stem cell transplant recipients
| Autor: | Buyck, Hubertus C, Prentice, H Grant, Griffiths, Paul D, Emery, Vincent C |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Risk Time Factors Adolescent Antibodies Neoplasm Cytomegalovirus Antineoplastic Agents In Vitro Techniques Antibodies Monoclonal Humanized Article immune response Cohort Studies Young Adult Risk Factors Humans CMV Disease Child Alemtuzumab Retrospective Studies Hematopoietic Stem Cell Transplantation virus diseases Antibodies Monoclonal Middle Aged replication kinetics Child Preschool Cytomegalovirus Infections DNA Viral Multivariate Analysis Female |
| Zdroj: | Bone marrow transplantation |
| ISSN: | 1476-5365 0268-3369 |
| Popis: | The risks associated with in vivo and ex vivo use of Campath-1H and -1G in a cohort of 206 stem cell transplant recipients for cytomegalovirus (HCMV) DNAemia have been quantified. DNAemia showed a biphasic incidence pattern with an inflexion at day 60. The first phase had a linear risk rate for HCMV DNAemia of 0.3 % day−1 whilst the second phase had a substantially lower risk rate of 0.058 % day−1. In multivariable analyses, risk factors for early DNAemia were HCMV serostatus, radiotherapy based conditioning and CD34 stem cell dose, with the use of in vivo Campath-1H having the most significant risk (Hazards Ratio = 3.68 (95% CI 2.02-6.72; p grade II and a lower CD34 stem cell dose whereas Campath-1H use was not associated with late HCMV DNAemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|